The process of drug discovery and development for infectious diseases is a multifaceted endeavor that encompasses various stages and disciplines. Initially, researchers embark on the quest for novel therapeutic agents by identifying promising drug targets within microbial pathogens. Utilizing cutting-edge technologies such as high-throughput screening and computational modeling, scientists screen vast libraries of compounds to pinpoint potential candidates with antimicrobial activity. Subsequently, selected compounds undergo rigorous preclinical testing to evaluate their safety, efficacy, and pharmacokinetic properties. Upon successful validation, promising candidates progress to clinical trials, where their therapeutic potential is assessed in human subjects. Throughout this journey, collaboration between academia, pharmaceutical companies, and regulatory agencies is essential to navigate the complex regulatory landscape and bring effective treatments to market, addressing the urgent global need for innovative therapies to combat infectious diseases.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Gendered socioeconomic impacts of emerging infectious diseases: Insights from a mixed-methods study in Guinea
Stephanie Maltais, University of Montreal, Canada
Title : The role of social sciences in operationalizing the One Health approach: A case study of the DOPERAUS project in Guinea and the Democratic Republic of Congo
Stephanie Maltais, University of Montreal, Canada